INBS preliminary Q2 revenue $0.76M (+114% YoY); six-month revenue $1.56M (+337%)

INTELLIGENT BIO SOLUTIONS INC.

2024-Q2 EPS reported -$7.68 vs consensus -$5.20 ▼ miss (-47.6%)

Preliminary unaudited Q2 FY2024 revenue ~$0.76M, up 114% vs prior year quarter.
Six-month revenue ~$1.56M, up 337% vs same period last year.
Cartridge sales rose ~30% and reader sales rose ~91% for the six-month period.
Growth driven by market expansion; New Zealand entry and planned Asia-Pacific push.
Results are preliminary; full Q2 report expected in Form 10-Q filed week of Feb 5, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTELLIGENT BIO SOLUTIONS INC. reported fiscal second quarter and six months ended December 31, 2023 results: revenue $0.76 million for the second fiscal quarter ended December 31, 2023.

Period: fiscal second quarter and six months ended December 31, 2023
Revenue: $0.76 million for the second fiscal quarter ended December 31, 2023
Result: preliminary results

Exact text from the filing

The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-004793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.